Why Is Tesla Stock Falling?
Tesla stock reached an all-time high of $479.86 on December…
Sell
46
TOVX Quote, Financials, Valuation and Earnings
Last price:
$1.69
Seasonality move
:
-9.16%
Day range:
$1.67 - $1.72
52-week range:
$1.14 - $17.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.59x
P/B ratio:
0.19x
Volume:
59.7K
Avg. volume:
233.1K
1-year change:
-86.06%
Market cap:
$4.7M
Revenue:
--
EPS (TTM):
-$33.18
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Theriva Biologics has 5207.92% upside to fair value with a price target of -- per share.
TOVX vs. S&P 500
-
Over the past 5 trading days, Theriva Biologics has overperformed the S&P 500 by 18.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Theriva Biologics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Theriva Biologics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Theriva Biologics reported revenues of --.
Earnings Growth
-
Theriva Biologics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Theriva Biologics reported earnings per share of -$6.81.
Enterprise value:
-11.5M
EV / Invested capital:
--
Price / LTM sales:
1.59x
EV / EBIT:
--
EV / Revenue:
-3.35x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.61x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$19.5M | -$22.5M | -$21.1M | -$4.2M | -$5M | |
| EBITDA | -$19.5M | -$22.4M | -$20.9M | -$4.2M | -$5M | |
| Diluted EPS | -$32.00 | -$31.85 | -$33.18 | -$4.85 | -$6.81 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.7M | $73.6M | $52.7M | $34.8M | $19.5M | |
| Total Assets | $7.2M | $75.1M | $78.7M | $61.5M | $40.1M | |
| Current Liabilities | $3M | $3.2M | $13.2M | $8.7M | $7.3M | |
| Total Liabilities | $3.3M | $4.6M | $20.5M | $17.7M | $15.5M | |
| Total Equity | $3.9M | $70.6M | $58.1M | $43.9M | $24.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.5M | -$17.8M | -$18.8M | -$3M | -$3.9M | |
| Cash From Investing | -$4.3M | -$237K | -$57K | -$129K | -- | |
| Cash From Financing | $1.4M | -$1.2M | $4M | $1K | $3.7M | |
| Free Cash Flow | -$18.5M | -$18.1M | -$18.8M | -$3.1M | -$3.9M | |
TOVX
Sector
Market Cap
$4.7M
$43.4M
Price % of 52-Week High
9.96%
48.26%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-86.07%
-34.26%
Beta (5-Year)
1.217
0.749
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.52
200-day SMA
Sell
Level
$3.88
Bollinger Bands (100)
Buy
Level
1.17 - 1.87
Chaikin Money Flow
Sell
Level
-603.7M
20-day SMA
Buy
Level
$1.42
Relative Strength Index (RSI14)
Buy
Level
61.58
ADX Line
Buy
Level
31.96
Williams %R
Sell
Level
-7.5
50-day SMA
Buy
Level
$1.42
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
630M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Stock Forecast FAQ
In the current month, TOVX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TOVX average analyst price target in the past 3 months is --.
-
Where Will Theriva Biologics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Theriva Biologics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Theriva Biologics?
Analysts are divided on their view about Theriva Biologics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Theriva Biologics is a Sell and believe this share price will drop from its current level to --.
-
What Is Theriva Biologics's Price Target?
The price target for Theriva Biologics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TOVX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Theriva Biologics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of TOVX?
You can purchase shares of Theriva Biologics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Theriva Biologics shares.
-
What Is The Theriva Biologics Share Price Today?
Theriva Biologics was last trading at $1.69 per share. This represents the most recent stock quote for Theriva Biologics. Yesterday, Theriva Biologics closed at $1.71 per share.
-
How To Buy Theriva Biologics Stock Online?
In order to purchase Theriva Biologics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is DoorDash a Buy, Sell or Hold?
Gig economy food delivery service DoorDash (NASDAQ:DASH) has been running…
Is Clorox’s Dividend Worth It?
Clorox (NYSE:CLX) is the parent company of some of the…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 116x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $3T
P/E Ratio: 35x
Alerts
Buy
87
PCOR alert for Feb 15
Procore Technologies [PCOR] is up 16.3% over the past day.
Buy
54
DKNG alert for Feb 15
DraftKings [DKNG] is up 15.24% over the past day.
Sell
30
TWLO alert for Feb 15
Twilio [TWLO] is down 15.01% over the past day.
